Literature DB >> 10974131

Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.

J L Shifren1, G D Braunstein, J A Simon, P R Casson, J E Buster, G P Redmond, R E Burki, E S Ginsburg, R C Rosen, S R Leiblum, K E Caramelli, N A Mazer.   

Abstract

BACKGROUND: The ovaries provide approximately half the circulating testosterone in premenopausal women. After bilateral oophorectomy, many women report impaired sexual functioning despite estrogen replacement. We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced menopause.
METHODS: Seventy-five women, 31 to 56 years old, who had undergone oophorectomy and hysterectomy received conjugated equine estrogens (at least 0.625 mg per day orally) and, in random order, placebo, 150 microg of testosterone, and 300 microg of testosterone per day transdermally for 12 weeks each. Outcome measures included scores on the Brief Index of Sexual Functioning for Women, the Psychological General Well-Being Index, and a sexual-function diary completed over the telephone.
RESULTS: The mean (+/-SD) serum free testosterone concentration increased from 1.2+/-0.8 pg per milliliter (4.2+/-2.8 pmol per liter) during placebo treatment to 3.9+/-2.4 pg per milliliter (13.5+/-8.3 pmol per liter) and 5.9+/-4.8 pg per milliliter (20.5+/-16.6 pmol per liter) during treatment with 150 and 300 microg of testosterone per day, respectively (normal range, 1.3 to 6.8 pg per milliliter [4.5 to 23.6 pmol per liter]). Despite an appreciable placebo response, the higher testosterone dose resulted in further increases in scores for frequency of sexual activity and pleasure-orgasm in the Brief index of Sexual Functioning for Women (P=0.03 for both comparisons with placebo). At the higher dose the percentages of women who had sexual fantasies, masturbated, or engaged in sexual intercourse at least once a week increased two to three times from base line. The positive-well-being, depressed-mood, and composite scores of the Psychological General Well-Being Index also improved at the higher dose (P=0.04, P=0.03, and P=0.04, respectively, for the comparison with placebo), but the scores on the telephone-based diary did not increase significantly.
CONCLUSIONS: In women who have undergone oophorectomy and hysterectomy, transdermal testosterone improves sexual function and psychological well-being.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974131     DOI: 10.1056/NEJM200009073431002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  98 in total

1.  Measurement of male and female sexual dysfunction.

Authors:  R C Rosen
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

Review 2.  Prevalence of and recent developments in female sexual dysfunction.

Authors:  R Shabsigh
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

3.  Menopause and hormone replacement: Part 1. Evaluation and treatment.

Authors:  S Ratner; D Ofri
Journal:  West J Med       Date:  2001-06

Review 4.  The impact of the new sexual pharmaceuticals on sex therapy.

Authors:  M A Perelman
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

Review 5.  Hormonal replacement therapy.

Authors:  Regine Sitruk-Ware
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 6.  Testosterone and heart failure.

Authors:  Maurizio Volterrani; Giuseppe Rosano; Ferdinando Iellamo
Journal:  Endocrine       Date:  2012-06-24       Impact factor: 3.633

7.  Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial.

Authors:  Grace Huang; Shehzad Basaria; Thomas G Travison; Matthew H Ho; Maithili Davda; Norman A Mazer; Renee Miciek; Philip E Knapp; Anqi Zhang; Lauren Collins; Monica Ursino; Erica Appleman; Connie Dzekov; Helene Stroh; Miranda Ouellette; Tyler Rundell; Merilyn Baby; Narender N Bhatia; Omid Khorram; Theodore Friedman; Thomas W Storer; Shalender Bhasin
Journal:  Menopause       Date:  2014-06       Impact factor: 2.953

Review 8.  Sexual function in women with pelvic floor disorders.

Authors:  Rebecca G Rogers
Journal:  Can Urol Assoc J       Date:  2013-09       Impact factor: 1.862

Review 9.  Female sexual dysfunction: potential for pharmacotherapy.

Authors:  Jean L Fourcroy
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause.

Authors:  Claudio N Soares; Jennifer R Poitras; Jennifer Prouty
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.